All In Biotech

Drug Trial Radar · NCT05671510

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 630 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

630

Planned (sponsor's estimate)

Start

Jun 28, 2023

Primary completion

Aug 31, 2027

Study completion Aug 31, 2028

Sponsor

Lead sponsor
OncoC4, Inc.Industry
Sponsor type
Industry
Collaborators
BioNTech SE
First posted
Jan 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once every 21 days, for up to 17 cycles in approximately one year.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • GotistobartDrug

    Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.

  • DocetaxelDrug

    Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: 36 months

Locations

152 sites in 12 countries. Site status is shown where the registry gives one.

  • XCancer/Dothan Hematology & Oncology - 1114

    Dothan, Alabama

  • Genesis Cancer and Blood Institute - 1123

    Russellville, Arkansas

  • The Oncology Institute (TOI) Clinical Research - 1109

    Cerritos, California

  • Emad Ibrahim MD Inc. - 1147

    Redlands, California

  • UC Davis Comprehensive Cancer Center - 1103

    Sacramento, California

  • Bass Medical Group - 1155

    Walnut Creek, California

  • Nuvance Health - 1118

    Norwalk, Connecticut

  • D&H Cancer Research Center LLC - 1153

    Margate, Florida

  • Ocala Oncology Center PL - 1102

    Ocala, Florida

  • AdventHealth Cancer Institute - 1105

    Orlando, Florida

  • Orlando Health - 1130

    Orlando, Florida

  • Florida Cancer Specialists -South - 1126

    Sarasota, Florida

  • Florida Cancer Specialists -North - 1125

    The Villages, Florida

  • Florida Cancer Specialists -East - 1124

    West Palm Beach, Florida

  • Orchard Healthcare Research, Inc. - 1116

    Skokie, Illinois

  • Springfield Clinic - The Cancer Center - 1110

    Springfield, Illinois

  • Fort Wayne Medical Oncology - 1133

    Fort Wayne, Indiana

  • Deaconess Chancellor Center for Oncology - 1131

    Newburgh, Indiana

  • Cotton O'Neil Clinical Research Center - 1151

    Topeka, Kansas

  • University of Kentucky - Markey Cancer Center - 1112

    Lexington, Kentucky

  • Norton Cancer Institute - 1108

    Louisville, Kentucky

  • Jefferson City Medical Group - 1145

    Jefferson City, Missouri

  • MidAmerica Cancer Care - 1163

    Kansas City, Missouri

  • Astera Cancer Care - 1128

    East Brunswick, New Jersey

  • Duke University Medical Center - 1158

    Durham, North Carolina

  • Miami Valley Hospital - 1115

    Centerville, Ohio

  • University of Cincinnati Cancer Center - 1107

    Cincinnati, Ohio

  • The Ohio State University James Cancer Center - 1104

    Columbus, Ohio

  • Tri County Hematology & Oncology Associates, Inc - 1156

    Massillon, Ohio

  • Oklahoma Cancer Specialists and Research Institute - 1154

    Tulsa, Oklahoma

  • Oncology Associates of Oregon - 1138

    Eugene, Oregon

  • St. Luke's University Health Network - 1179

    Bethlehem, Pennsylvania

  • Donald Guthrie Foundation - 1135

    Sayre, Pennsylvania

  • Cancer Care Associates of York, Inc. - 1113

    York, Pennsylvania

  • University of Tennessee Medical Center - 1146

    Knoxville, Tennessee

  • Sarah Cannon Research Institute - Tennessee Oncology at Nashville - 1119

    Nashville, Tennessee

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center (USOR) - 1140

    Dallas, Texas

  • Texas Oncology - Denison - 1139

    Denison, Texas

  • Oncology Consultants, P.A. - 1120

    Houston, Texas

  • Oncology and Hematology of South Texas - 1165

    Laredo, Texas

Showing 40 of 152 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.